| CPC C07K 16/2887 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)] | 20 Claims |
|
1. A method for treating a human subject with a CD20-expressing cancer, comprising:
administering to the human subject a bispecific anti-CD20×anti-CD3 antibody in a first phase, a second phase, a third phase, a fourth phase, and a fifth phase,
wherein in the first phase the bispecific anti-CD20×anti-CD3 antibody is administered once to the human subject in a first phase dose amount between about 0.5 mg and about 1.1 mg,
in the second phase the bispecific anti-CD20×anti-CD3 antibody is administered once to the human subject in a second phase dose amount between about 1.5 mg and about 2.5 mg,
in the third phase the bispecific anti-CD20×anti-CD3 antibody is administered once to the human subject in a third phase dose amount between about 18 mg and about 22 mg,
in the fourth phase the bispecific anti-CD20×anti-CD3 antibody is administered once to the human subject in a fourth phase dose amount between about 30 mg and about 55 mg,
in the fifth phase the bispecific anti-CD20×anti-CD3 antibody is administered at least once to the human subject in a fifth phase dose amount between about 45 mg and about 55 mg,
wherein the time period between each administration is about 6 to about 8 days, wherein each of the first phase dose amount to the fifth phase dose amount is independent of the weight of the human subject, and
wherein the bispecific anti-CD20×anti-CD3 antibody comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO:1, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2, and a third polypeptide comprising the amino acid sequence of SEQ ID NO: 3.
|